First Manhattan’s Teva Pharmaceuticals TEVA Stock Holding History

First Manhattan’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.32M	Buy	43,675 +2,000	+5%	+$64.3K	﹤0.01%	392
2025 Q4	$1.3M	Buy	41,675 +20,000	+92%	+$493K	﹤0.01%	397
2025 Q3	$438K	Hold	21,675	–	–	﹤0.01%	566
2025 Q2	$363K	Hold	21,675	–	–	﹤0.01%	589
2025 Q1	$333K	Sell	21,675 -40,000	-65%	-$715K	﹤0.01%	570
2024 Q4	$1.36M	Buy	61,675 +41,175	+201%	+$749K	﹤0.01%	350
2024 Q3	$369K	Hold	20,500	–	–	﹤0.01%	550
2024 Q2	$333K	Hold	20,500	–	–	﹤0.01%	553
2024 Q1	$289K	Hold	20,500	–	–	﹤0.01%	592
2023 Q4	$214K	Hold	20,500	–	–	﹤0.01%	638
2023 Q3	$209K	Hold	20,500	–	–	﹤0.01%	649
2023 Q2	$154K	Hold	20,500	–	–	﹤0.01%	695
2023 Q1	$181K	Sell	20,500 -517	-2%	-$5.11K	﹤0.01%	694
2022 Q4	$192K	Buy	21,017 +357	+2%	+$3.12K	﹤0.01%	707
2022 Q3	$166K	Sell	20,660 -247	-1%	-$2.18K	﹤0.01%	726
2022 Q2	$157K	Buy	20,907 +1	+0%	+$9	﹤0.01%	757
2022 Q1	$196K	Sell	20,906 -238,862	-92%	-$1.99M	﹤0.01%	762
2021 Q4	$2.08M	Buy	259,768 +2	+0%	+$18	0.01%	340
2021 Q3	$2.53M	Buy	259,766 +9,972	+4%	+$93.4K	0.01%	302
2021 Q2	$2.47M	Sell	249,794 -5,753	-2%	-$60.9K	0.01%	304
2021 Q1	$2.95M	Hold	255,547	–	–	0.01%	283
2020 Q4	$2.47M	Buy	255,547 +4,302	+2%	+$41.2K	0.01%	296
2020 Q3	$2.26M	Buy	251,245 +1,468	+0.6%	+$15.5K	0.01%	284
2020 Q2	$3.08M	Sell	249,777 -57,500	-19%	-$650K	0.02%	260
2020 Q1	$2.76M	Hold	307,277	–	–	0.02%	269
2019 Q4	$3.01M	Buy	307,277 +9,900	+3%	+$88.4K	0.02%	286
2019 Q3	$2.04M	Sell	297,377 -7	-0%	-$54	0.01%	325
2019 Q2	$2.74M	Sell	297,384 -24,070	-7%	-$290K	0.02%	298
2019 Q1	$5.04M	Buy	321,454 +4,832	+2%	+$85.2K	0.03%	233
2018 Q4	$4.88M	Buy	316,622 +1,455	+0.5%	+$29.8K	0.03%	239
2018 Q3	$6.79M	Sell	315,167 -10,256	-3%	-$238K	0.04%	231
2018 Q2	$7.91M	Sell	325,423 -1,003,907	-76%	-$20.5M	0.05%	210
2018 Q1	$22.7M	Sell	1,329,330 -1,520	-0.1%	-$29.7K	0.13%	118
2017 Q4	$25.2M	Sell	1,330,850 -208,394	-14%	-$3.13M	0.14%	112
2017 Q3	$27.1M	Buy	1,539,244 +31,854	+2%	+$717K	0.16%	109
2017 Q2	$50.1M	Buy	1,507,390 +800	+0.1%	+$24.8K	0.29%	65
2017 Q1	$48.3M	Buy	1,506,590 +54,958	+4%	+$1.88M	0.29%	69
2016 Q4	$52.6M	Buy	1,451,632 +952,074	+191%	+$38M	0.32%	61
2016 Q3	$23M	Sell	499,558 -917	-0.2%	-$47.8K	0.14%	115
2016 Q2	$25.1M	Buy	500,475 +590	+0.1%	+$31.4K	0.15%	107
2016 Q1	$26.7M	Sell	499,885 -510	-0.1%	-$29.9K	0.16%	97
2015 Q4	$32.8M	Sell	500,395 -11,763	-2%	-$727K	0.2%	88
2015 Q3	$28.9M	Sell	512,158 -28,935	-5%	-$1.88M	0.19%	91
2015 Q2	$32M	Sell	541,093 -9,587	-2%	-$591K	0.19%	94
2015 Q1	$34.3M	Sell	550,680 -2,203	-0.4%	-$128K	0.2%	86
2014 Q4	$31.8M	Sell	552,883 -33,852	-6%	-$1.89M	0.18%	99
2014 Q3	$31.5M	Sell	586,735 -1,020	-0.2%	-$54K	0.18%	94
2014 Q2	$30.8M	Sell	587,755 -2,765	-0.5%	-$141K	0.2%	93
2014 Q1	$31.2M	Buy	590,520 +3,596	+0.6%	+$166K	0.21%	92
2013 Q4	$23.5M	Sell	586,924 -39,101	-6%	-$1.54M	0.16%	112
2013 Q3	$23.7M	Sell	626,025 -63	-0%	-$2.46K	0.17%	102
2013 Q2	$25M	Buy	+626,088	New	+$24.4M	0.17%	95

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan's TEVA Position: Q1 2026 in Review

First Manhattan increased its Teva Pharmaceuticals (TEVA) stake by 4.8% in Q1 2026, buying an estimated $64.3K and bringing the position to 43,675 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #392.

First Manhattan first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $52.6M in Q4 2016. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

First Manhattan held 43,675 shares of Teva Pharmaceuticals worth $1.32M as of Q1 2026.
First Manhattan bought 2,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $64.3K.
Teva Pharmaceuticals made up ﹤0.01% of First Manhattan's portfolio in Q1 2026, its #392 holding.
First Manhattan first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
First Manhattan's Teva Pharmaceuticals position peaked at $52.6M in Q4 2016.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on First Manhattan's 13F filing for Q1 2026, filed 15 May 2026.